Sequenom Laboratories Presents New Data on the Enhanced Sequencing Series for the MaterniT21™ Plus Laboratory-Developed Test

Sequenom Laboratories Presents New Data on the Enhanced Sequencing Series for
     the MaterniT21™ Plus Laboratory-Developed Test At 18th International
                 Conference on Prenatal Diagnosis and Therapy

PR Newswire

SAN DIEGO, July 22, 2014

SAN DIEGO, July 22, 2014 /PRNewswire/ --Sequenom, Inc. (NASDAQ: SQNM), a life
sciences company providing innovative genetic analysis solutions, today
announced its wholly owned subsidiary, Sequenom Laboratories, will soon begin
reporting on the presence of three additional clinically relevant
subchromosomal microdeletions as part of the Enhanced Sequencing Series (ESS)
for its MaterniT21™ PLUS laboratory-developed test. The microdeletions added
include 11q deletion (Jacobsen syndrome), 8q deletion (Langer-Giedion
syndrome), and 4p deletion (Wolf-Hirschhorn syndrome) and will be reported as
an additional finding when a positive result is detected. New study data on
the Enhanced Sequencing Series was presented at the 18^th International
Conference on Prenatal Diagnosis and Therapy (ISPD) in Brisbane Australia.

SEQUENOM logo.

"The MaterniT21 PLUS test has helped change how we treat our prenatal
patients, and its ability to screen for several microdeletions exemplifies the
growth and potential of this technology," said Jeff Chapa, MD, Head of the
Section of Maternal-Fetal Medicine in Cleveland Clinic Department of
Obstetrics and Gynecology. "With the Enhanced Sequencing Series, I can provide
my patients with this clinically relevant information as early as 10 weeks
into a pregnancy."

These microdeletions are associated with various clinical conditions that can
result in physical and developmental issues. Jacobsen syndrome, which is
caused by a deletion on the long arm of chromosome 11, is characterized by
growth restriction, developmental delay, distinctive facial features, and a
bleeding disorder called Paris-Trousseau syndrome. Langer-Giedion syndrome,
caused by a deletion on the long arm of chromosome 8, is characterized by bone
abnormalities and may be associated with developmental delays. Wolf-Hirschhorn
syndrome is caused by a deletion on the short arm of chromosome 4 and is
characterized by distinctive craniofacial anomalies, growth restriction,
developmental delay, hearing loss and seizures.

This expansion complements the MaterniT21 PLUS test original Enhanced
Sequencing Series of clinically relevant microdeletions which Sequenom
Laboratories began reporting in October 2013. Included were 22q11.2 deletion
(DiGeorge syndrome), 5p minus (Cri-du-chat syndrome), 15q deletion
(Prader-Willi/Angelman syndromes), 1p36 deletion syndrome, as well as two
additional trisomies, (trisomy 16 and 22).

"Leveraging our advanced, whole genome technology, we are able to offer more
comprehensive prenatal information to health care providers and their
patients," said Dirk van den Boom, PhD, Chief Scientific and Strategy Officer
at Sequenom, Inc. "We have received very positive response to the Enhanced
Sequencing Series. This set of microdeletions added to our MaterniT21 PLUS
test is the next extension of the Enhanced Sequencing Series and continues our
path towards the vision of a noninvasive fetal karyotype."

Sequenom Laboratories first pioneered the use of noninvasive prenatal testing
(NIPT) in 2011. With this expansion, the MaterniT21 PLUS test is the
first-of-its-kind NIPT to provide these comprehensive results from a maternal
blood draw. The MaterniT21 PLUS test was developed, validated and is performed
exclusively by Sequenom Laboratories.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genomic and genetic analysis
solutions. Sequenom develops innovative technology, products and diagnostic
tests that target and serve molecular diagnostic markets. Website:
www.sequenom.com.

About Sequenom Laboratories
Sequenom Laboratories, a CAP accredited and CLIA-certified molecular
diagnostics laboratory, has developed a broad range of laboratory tests, with
a focus on prenatal and ophthalmological diseases and conditions. Branded
under the name HerediT™, MaterniT21™ PLUS, RetnaGene™, SensiGene™ and
VisibiliT™, these molecular genetic laboratory-developed tests provide early
patient management information for obstetricians, geneticists, maternal fetal
medicine specialists and ophthalmologists. Sequenom Laboratories is changing
the landscape in genetic disorder diagnostics using proprietary cutting edge
technologies.

SEQUENOM®, HerediT™, MaterniT21™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™,
are trademarks of Sequenom, Inc. All other trademarks and service marks are
the property of their respective owners.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding Sequenom's expected
launch of Sequenom Laboratories' Enhanced Sequencing Series for its MaterniT21
PLUS test, the impact and benefits of the Enhanced Sequencing Series on
patients and health care providers, Sequenom's vision of a noninvasive fetal
karyotype, Sequenom's commitment to improving healthcare through revolutionary
genomic and genetic analysis solutions, and Sequenom Laboratories' changing
the landscape in genetic disorder diagnostics, are forward-looking statements
within the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ materially,
including the risks and uncertainties associated with Sequenom's ability to
develop and commercialize new technologies and products, particularly new
technologies such as prenatal and other diagnostics and laboratory developed
tests, Sequenom's ability to manage its existing cash resources or raise
additional cash resources, competition, intellectual property protection and
intellectual property rights of others, government regulation particularly
with respect to diagnostic products and laboratory developed tests, obtaining
or maintaining regulatory approvals, ongoing patent litigation, and other
risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly and
Annual Reports on Securities and Exchange Commission Forms 10-Q and 10-K,
respectively, and other documents subsequently filed with or furnished to the
Securities and Exchange Commission. These forward-looking statements are based
on current information that may change and you are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date of this press release. All forward-looking statements are qualified in
their entirety by this cautionary statement, and Sequenom undertakes no
obligation to revise or update any forward-looking statement to reflect events
or circumstances after the issuance of this press release.

Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

SOURCE Sequenom, Inc.

Website: http://www.sequenom.com
Contact: Carolyn Beaver, Chief Financial Officer, Sequenom, Inc.,
858-202-9028, investorrelations@sequenom.com; or Rachel Kennedy, Media
Contact, Chandler Chicco Agency, 858-449-9575,
rkennedy@chandlerchiccocompanies.com
 
Press spacebar to pause and continue. Press esc to stop.